https://www.selleckchem.com/pr....oducts/Menadione.htm
. . Epidermal growth factor receptor (EGFR) mutation status is used as a predictive biomarker for the tyrosine kinase inhibitors therapy in non-small cell lung cancer (NSCLC). The incidence of EGFR mutations appears to vary according to ethnic and geographical backgrounds. This retrospective study aimed to investigate the EGFR mutation status in Algerian NSCLC patients and its association with clinicopathological features. We examined the presence of EGFR mutations (Exons 19-21) in 58 unselected NSCLC samples using PCR followed
Like
Comment
Share
